Results 151 to 160 of about 50,888 (294)

Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer

Molecular Oncology, EarlyView.
PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta, Yang Song, Madeleine Ndahayo, Anirudh Saxena, Theresa Guo, Dylan Z. Kelley, Jessica Gore, Andrew Hennigan, Alexa Anderson, John C. Papadimitriou, Daria A. Gaykalova   +10 more
wiley   +1 more source

The “Big Three” in biocompatibility testing of medical devices: implementation of alternatives to animal experimentation—are we there yet? [PDF]

Helena Kanďárová, P. Pôbiš
openalex   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Choosing Less Harmful Alternatives: The Ethics of Harm Reduction in Emerging Technologies. [PDF]

Sci Eng Ethics
Turner C.
europepmc   +1 more source

Airborne toxicological assessment: The potential of lung-on-a-chip as an alternative to animal testing

, 2022
Ko-Chih Lin, Chien-Mei Yen, Jia‐Wei Yang, Johnson Chung, G.-Y. Chen   +4 more
openalex   +1 more source

Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity

Molecular Oncology, EarlyView.
Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek, Jenny Sprooten, Abhishek D. Garg   +2 more
wiley   +1 more source

Alternatives to animal testing are the future — it’s time that journals, funders and scientists embrace them

Todd J. Herron, Anke Brüning‐Richardson, Julie E. Gough, Aline F. Miller, Geoffrey J. Pilkington, John Greenman, Valerie Speirs, Joseph C. Wu   +7 more
openalex   +2 more sources

Rethinking plastic waste: innovations in enzymatic breakdown of oil‐based polyesters and bioplastics

FEBS Open Bio, EarlyView.
Plastic pollution remains a critical environmental challenge, and current mechanical and chemical recycling methods are insufficient to achieve a fully circular economy. This review highlights recent breakthroughs in the enzymatic depolymerization of both oil‐derived polyesters and bioplastics, including high‐throughput protein engineering, de novo ...
Elena Rosini, Nicolò Antonelli, Gianluca Molla   +2 more
wiley   +1 more source

The FDA's plan to phase out animal testing. [PDF]

Trends Biotechnol
Gerke S, Balamut J, Wagner JK.
europepmc   +1 more source